BPC-157 Safety: What Toxicology, Human Data and Regulators Say

“Is BPC-157 safe?” is one of the most searched questions about any research peptide, and it deserves a straight answer: nobody can say yet, because the studies that would settle it have not been done. What does exist is a reassuring but limited animal safety record, three very small human reports, one theoretical worry about blood-vessel growth, and a regulatory picture that changed quickly in 2026.

This guide separates what is known from what is assumed and what is simply missing, so you can read any claim about BPC-157 safety with the right amount of skepticism.

What “safe” would actually require

Before any new medicine reaches people, regulators expect a standard package of safety evidence: toxicity studies in at least two animal species, pharmacokinetics showing how the body absorbs, distributes and clears the compound, tests for genetic and reproductive effects, long-term studies for anything meant to be used for months, and then carefully escalated human trials with a control group. Measured against that package, here is where BPC-157 stands.

The pattern is clear. The early, animal end of the package is in reasonable shape. Almost everything that would tell us about safety in people is missing.

What the animal studies found

BPC-157 has one of the largest preclinical literatures of any research peptide, most of it from Predrag Sikirić’s group at the University of Zagreb. A 2025 systematic review for orthopaedic sports medicine screened 544 articles published between 1993 and 2024 and kept 36 that met its criteria. Thirty-five of the 36 were preclinical. Across tendon, ligament, muscle, bone and gut injury models in rodents, treated animals tended to heal faster or more completely, and the reviewers found no adverse effects reported in the preclinical safety work.

The most useful single safety study comes from a Chinese team developing BPC-157 as a wound-healing drug. Their 2020 preclinical evaluation tested it in mice, rats, rabbits and dogs and reported that it was well tolerated, with no serious toxic effects. A 2022 follow-up by the same group mapped its pharmacokinetics in rats and dogs and found that the intact peptide is cleared from the blood quickly.

Two caveats matter. Most of the efficacy literature comes from one laboratory, and independent replication is limited. And healthy-animal toxicology answers a narrow question, whether the compound harms healthy animals at the exposures tested, not whether long-term exposure is safe in people.

What the human studies found

The entire peer-reviewed human literature on BPC-157 fits in a short list. All three published studies come from the same US clinic and appeared in the same journal, Alternative Therapies in Health and Medicine.

1. 2021: knee painA retrospective look back at clinic patients who had received BPC-157 injections into the knee, some alone and some with other peptides. The authors reported pain improvement among patients they surveyed, but there was no control group, no blinding and no standardized protocol.
2. 2024: interstitial cystitisA pilot in 12 women with this painful bladder condition, who received BPC-157 injected into the bladder. The authors reported symptom improvement, again without a control group.
3. 2025: intravenous safetyTwo healthy adults received intravenous BPC-157 in a dose-escalation pilot. No adverse effects were reported.

Beyond these, early industry trials for inflammatory bowel disease were reported only as conference abstracts, and a phase 1 safety trial registered in 2015 has not published results. The 2025 systematic review’s conclusion was blunt: BPC-157 shows promise in animal models, but its safety in humans remains unknown.

Small, uncontrolled reports can generate hypotheses. They cannot establish safety, because they are too small to detect uncommon harms and have nothing to compare against.

Does BPC-157 cause cancer?

The cancer worry comes from biology, not from any study or case report. In animal experiments, BPC-157 promotes angiogenesis, the growth of new blood vessels. A 2017 study in rats linked this effect to activation and increased production of VEGFR2, the main receptor for vascular endothelial growth factor. New blood vessels help injured tissue heal. They also help established tumours grow beyond a tiny size, which is why some cancer drugs, such as bevacizumab, work by blocking the VEGF pathway.

Here is what the evidence does and doesn’t say:

• No published study shows that BPC-157 causes cancer in animals or people.
• No published study was designed to look for it either. Formal carcinogenicity studies, standard for drugs intended for long-term use, have not been published for BPC-157.
• The theoretical concern centres on existing tumours, which depend on new blood supply to grow, rather than on healthy cells turning cancerous.

In short, both “BPC-157 causes cancer” and “BPC-157 is proven not to cause cancer” go beyond the evidence. The honest answer is that the question is open.

What regulators say in 2026

Regulatory positions moved quickly over the past year. As of October 2026:

1. 2023: the US FDA flags safety risksThe FDA places BPC-157 in Category 2 of substances nominated for pharmacy compounding, the group that raises significant safety risks, citing concerns that included immunogenicity, peptide-related impurities and limited human data.
2. April 9, 2026: Health Canada warningHealth Canada warns Canadians not to buy or use unauthorized injectable peptides sold online and lists BPC-157 among products it has seized. It states that “For Research Use Only” labelling does not make such products legal or exempt from regulatory requirements.
3. Spring 2026: the FDA reopens its reviewThe FDA removes BPC-157 from Category 2 and refers it to its Pharmacy Compounding Advisory Committee. Removal alone does not make it eligible for compounding.
4. July 23, 2026: a split advisory voteFDA staff recommend against adding BPC-157 to the compounding list, citing short, underpowered studies. The committee votes 8 to 6, with one abstention, to recommend adding it for the nominated use of ulcerative colitis.
5. Next: an FDA decisionThe vote is advice, not a decision. BPC-157 has not been added to the list and is not an FDA-approved drug. Adding it would require formal rulemaking.

In Canada, BPC-157 has never been authorized as a drug and has no Drug Identification Number (DIN). Health Canada notes that peptides are generally regulated in Canada as prescription drugs, and that authorized prescription drugs carry an eight-digit DIN.

In sport, the World Anti-Doping Agency names BPC-157 in class S0, non-approved substances, which are prohibited at all times. Canadian athletes are tested under the Canadian Anti-Doping Program, which applies that list.

Product quality is a safety issue too

For laboratory work, an impure or wrong peptide is first a data problem: it undermines every result. It is also a safety issue in its own right. Health Canada warns that unauthorized peptide products may contain too much, too little or none of the claimed ingredient, and synthetic peptides can carry truncated sequences, residual solvents or bacterial endotoxin that a purity percentage alone won’t reveal.

A useful BPC-157 certificate of analysis should show:

• Identity by mass spectrometry. The measured mass should match about 1,419.5 g/mol. Electrospray instruments often report it as a doubly charged ion near m/z 710.
• Purity by HPLC, with the method and chromatogram, not just a number. See our HPLC testing guide.
• A lot number that matches your vial and the name of the laboratory that ran the tests. Our COA guide walks through every field.
• The salt form, since acetate and other forms change how much of the powder is actually peptide. See net peptide content and salt forms.
• Endotoxin data if your assay needs it. Most research COAs don’t include endotoxin testing, which matters for sensitive cell-culture work.

For the warning signs of a bad product, see how to spot fake or underdosed research peptides.

Sourcing BPC-157 for research in Canada

Pure Peptides Canada supplies BPC-157 as a lyophilized laboratory reagent, on its own and in research blends. Each listing links to its batch documentation.

BPC-157The 15-amino-acid peptide on its ownView product and COA BPC-157 + TB-500The classic two-peptide repair pairingView product and COA KLOW blendGHK-Cu, BPC-157, TB-500 and KPVView product and COA Coremend blendTB-500, KPV and BPC-157View product and COA

Frequently asked questions